Skip to main
IGC

IGC Stock Forecast & Price Target

IGC Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

IGC Pharma is a potential stock to buy as it has a large market potential with the company's focus on developing cannabinoid-based treatments, including its investigational drugs targeting Alzheimer's disease, which has no known cure, slow progression, or means of prevention. The ongoing Phase 2 trial for IGC-AD1 has reported positive interim results, demonstrating a clinical and statistically significant reduction in agitation. With upcoming milestones for the completion of its CALMA trial, and the release of its AI beta program in mid-2026, and a current attractive valuation, IGC Pharma presents high rewards for the risks and potential catalysts for the stock.

Bears say

IGC Pharma is facing a shift in their fiscal year and may face challenges in accurately reporting financial data and projecting future earnings as a result. Furthermore, despite recent progress in patient enrollment for their Phase 2 CALMA trial, the company's investigational drugs are yet to be proven effective and face potential regulatory hurdles. These factors contribute to a negative outlook on the stock.

IGC has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About India Globalization Capital (IGC) Forecast

Analysts have given IGC a Strong Buy based on their latest research and market trends.

According to 1 analysts, IGC has a Strong Buy consensus rating as of Aug 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

India Globalization Capital (IGC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.